RecruitingPhase 2NCT07745426

Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis


Sponsor

Tanta University

Enrollment

66 participants

Start Date

Aug 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The patients will be randomized into three groups: \- Group 1 (control group): will include 22 patients who will receive the conventional therapy for RA for 3 months. \- Group 2 (diosmin group): will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months. \- Group 3 (rebamipide group): will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria4

  • Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR). i.e.,28 joints disease activity score (DAS-28) >2.6.
  • Both sexes.
  • Age ranges between 18 and 70 years old.
  • Patients receiving conventional DMARDs

Exclusion Criteria7

  • Pregnant and lactating females.
  • Patients receiving biological DMARDs or targeted synthetic DMARDs.
  • Patients with renal and hepatic dysfunction.
  • Patients with other inflammatory/autoimmune diseases, active infection, or malignancies.
  • Patients with bleeding disorders, receiving warfarin or other anticoagulants.
  • Patients receiving antioxidants.
  • Patients with hypersensitivity to study medications.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDiosmin

1000 mg diosmin once daily for 3 months

DRUGRebamipide 100mg

100 mg rebamipide three times daily for 3 months

DRUGConvential medical treatment

conventional medical treatment for RA


Locations(1)

Faculty of Pharmacy Tanta University

Tanta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07745426


Related Trials